Skip to main content
Medical information Clinical review pending

Cytogenetics

Immunohistochemistry WT1 Test

The Immunohistochemistry WT1 Test helps identify the WT1 protein, often associated with specific cancers like Wilms' tumor. It aids in diagnosis and management.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Tumor tissue sample, either in 10% Formal-saline or Formalin fixed paraffin embedded block.
Results
Report Block: 5 days; Tissue Biopsy: 5 days; Tissue Large Complex: 7 days. Confirm with the laboratory before booking.
Preparation
No patient preparation is required. Ensure the sample is correctly labeled and accompanied by a copy of the Histopathology report, site of biopsy, and clinical history.
Test priceKSh 7,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Immunohistochemistry WT1 Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Diagnosis of Wilms' tumor
  • ✓Evaluation of certain adult cancers
  • ✓Assessment of tumor aggressiveness
  • ✓Guiding treatment strategies
  • ✓Monitoring response to therapy
  • ✓Patients with relevant symptoms or family history
02

In plain language

What this test helps you understand

Aids in the diagnosis and management of cancers associated with WT1 protein expression, such as Wilms' tumor and certain adult malignancies. Helps guide treatment decisions and monitor disease progression.
The Immunohistochemistry WT1 Test is an advanced diagnostic procedure used primarily to detect the presence of the WT1 protein. This protein is associated with certain types of cancers, particularly Wilms' tumor in children and various adult cancers. This test is invaluable in aiding oncologists and pathologists in diagnosing and managing cancer more effectively.

This test specifically measures the expression of the WT1 protein in tumor tissue samples. By identifying the presence or absence of this protein, healthcare providers can gain insights into the type of cancer present and its potential aggressiveness.

Results from the Immunohistochemistry WT1 Test will indicate whether the WT1 protein is present in the tissue sample. A positive result may suggest the presence of cancer, while a negative result can help rule out certain malignancies. It is essential to discuss your results with your healthcare provider to understand their implications fully.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo patient preparation is required. Ensure the sample is correctly labeled and accompanied by a copy of the Histopathology report, site of biopsy, and clinical history.
SampleTumor tissue sample, either in 10% Formal-saline or Formalin fixed paraffin embedded block.
MethodologyImmunohistochemistry (IHC) technique using antibodies specific to the WT1 protein.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects the presence of the WT1 protein but does not provide a definitive cancer diagnosis on its own. Results must be interpreted in the context of clinical findings and other diagnostic tests. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

WT1 is a protein associated with the development of certain cancers, particularly Wilms' tumor in children.
This test is primarily used for Wilms' tumor and certain other adult cancers where WT1 expression is relevant.
A tumor tissue sample, typically a paraffin-embedded block or a biopsy specimen, is required.
Turnaround time varies depending on the sample type, typically ranging from 5 to 7 days. Confirm with the laboratory before booking.
Results indicate the presence or absence of the WT1 protein in the tissue. Your doctor will interpret these results in the context of your overall health.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp